Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 13, 2007 Brian Orelli	Merck's Vaccination Woes Merck announces it is recalling 1.2 million doses of a vaccine that immunizes children against Hib, which causes meningitis, pneumonia, and other serious infections.
The Motley Fool November 19, 2009 Brian Orelli	Pfizer Dodges a Bullet The drugmaker slips through an advisory committee unscathed.
BusinessWeek July 25, 2005 Catherine Arnst	O.K., Roll Up Your Sleeve New vaccines are arriving but the economics are still a challenge.
The Motley Fool August 21, 2009 Brian Orelli	Forget Swine Flu: The Big Money Is Here Vaccines are pharma's, and possibly investors', best friend.
The Motley Fool March 7, 2011 Brian Orelli	Kids, Vaccines, and Deaths a Bad Combination Pfizer and Sanofi may not to be to blame, but when investing in drugmakers, you always have to be worried about drug safety. Fortunately this doesn't look like one of those issues.
The Motley Fool June 26, 2008 Brian Lawler	Gauging Glaxo's Vaccine Value Surprise! The FDA actually approves Glaxo's new combination children's vaccine without delay.
The Motley Fool February 25, 2010 Brian Orelli	13 Is Pfizer's Lucky Number Inherited from Wyeth, Prevnar 13 could be a goldmine for Pfizer.
The Motley Fool February 23, 2010 Brian Orelli	The End of a Swine Flu Era A Food and Drug Administration advisory panel recommended yesterday that next year's seasonal flu vaccine contain the vaccine for the H1N1 virus, aka the swine flu.
The Motley Fool July 1, 2008 Brian Lawler	FDA News Gives Glaxo a Glimmer of Hope Approval is delayed, but new studies won't be needed for Cervarix.
The Motley Fool July 7, 2009 Brian Orelli	Glaxo Missed the Boat The HPV vaccine market is declining before Glaxo can hop aboard.
The Motley Fool October 19, 2009 Brian Orelli	The HPV Vaccine Wars of 2010 Merck and GlaxoSmithKline human papillomavirus vaccines were both approved by the Food and Drug Administration for different indications.
The Motley Fool September 10, 2009 Brian Orelli	The Vanishing Vaccine War And it had such potential to be a bloodbath.
Pharmaceutical Executive February 1, 2009 Joanna Breitstein	Vaccines for All The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most.
The Motley Fool March 29, 2011 Brian Orelli	Much More Than a Generic Lawsuit The Supreme Court will decide generic-drug makers fate.
Pharmaceutical Executive May 1, 2006 Joanna Breitstein	Cervical Cancer: Endagered Species Preventive care is more efficient than treating disease after the fact. Now this paradigm takes hold in cancer with new HPV vaccines. Now that the science is in order, Merck and GSK face several important challenges in conditioning the market.
The Motley Fool November 13, 2008 Brian Orelli	Merck Could Double Potential Customers Merck's HPV vaccine, Gardasil, which is now recommended for girls and women is also shown to benefit boys and men.
The Motley Fool April 6, 2010 Brian Orelli	Kill It! Double-Teaming Malaria Malaria vaccine might not make Glaxo and Crucell rich, but the life-saving and PR benefits would be welcome.
HBS Working Knowledge March 1, 2004 Martha Lagace	Injecting New Life into the Vaccine Industry Vaccines for preventable diseases save millions of lives every year, yet as an industry, the vaccine business suffers a host of ailments, the CEO of Merck & Co. contends.
The Motley Fool November 13, 2007 Brian Orelli	Merck: Case Closed? Now that Merck has settled its lawsuit, it can get back to business, focusing on continued growth from its cholesterol drugs, new diabetic medication, and cervical cancer vaccine. Investors, take note.
Scientific American February 2006	To Banish a Cancer Two vaccines that are nearing approval by the Food and Drug Administration in the U.S. have demonstrated in clinical trials that they can prevent infection from the two types of the human papillomavirus (HPV) that account for up to 70 percent of cervical cancers.
American Family Physician December 1, 2002 Sanford R. Kimmel	Vaccine Adverse Events: Separating Myth from Reality Vaccines have turned many childhood diseases into distant memories in industrialized countries. However, questions have been raised about the safety of some vaccines because of rare but serious adverse effects that have been attributed to them.
The Motley Fool May 8, 2009 Brian Orelli	Glaxo Goes Head-to-Head on HPV Glaxo's data may not be enough to help Cervarix knock Merck's Gardasil from the top papillomavirus vaccine spot.
The Motley Fool July 20, 2007 Brian Lawler	Glaxo Heats Up the Vaccine Battle GlaxoSmithKline's cervical cancer vaccine gets a positive recommendation in the EU. Sales could begin in early 2008 and will compete with Gardasil, by rival Merck.
Salon.com March 8, 2001 Amy Standen	Ready for some lockjaw? There's no profit in the tetanus vaccine business, so a rare and hideous disease may soon strike more Americans...
BusinessWeek November 29, 2004 Kerry Capell	"A Vaccine Every Woman Should Take" Two drug companies are closing in on shots against HPV, the leading cause of cervical cancer. Despite the obvious benefits, the vaccines may not be an easy sell: There are social and moral hurdles to overcome.
The Motley Fool May 30, 2008 Brian Orelli	For Merck, Hindsight Hurts Even after dragging its feet for years, one has to wonder if Merck settled the Vioxx cases a little too quickly?
The Motley Fool October 7, 2005 Brian Gorman	Merck's Tricky Sell A vaccine for human papillomavirus clears scientific hurdles, but marketing could prove its biggest obstacle.
The Motley Fool March 5, 2009 Brian Orelli	The Dilemma for Drugmakers There's no safe place to hide.
The Motley Fool September 25, 2007 Brian Orelli	Cold HIV Vaccine Gets Frozen Phase 2 clinical trials of Merck's HIV vaccine were frozen, leaving the door open for other drugmakers that have vaccines of their own in early trials. Investors, take note.
The Motley Fool March 2, 2010 Brian Orelli	Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off.
Pharmaceutical Executive August 1, 2008 Patrick Clinton	Cutter's Way It's time to get drug cases out of the courts entirely.
The Motley Fool December 5, 2007 Brian Orelli	Merck Stays Conservative Merck sets the bar low with its 2008 guidance. Is the company being overly cautious?
Pharmaceutical Executive December 1, 2005 Sarah Houlton	Global Report: Wanted: Attention Bird flu is number one on the media's agenda. But other diseases need better immunization, too. WHO estimates that in 2002, 2.1 million people died from diseases that could have been prevented by vaccines that WHO currently recommends.
The Motley Fool April 4, 2007 Brian Lawler	GlaxoSmithKline Gets Ready for the Vaccine Wars British pharmaceutical powerhouse GlaxoSmithKline submits a marketing application to the FDA for its HPV vaccine. Investors, take note.
Pharmaceutical Executive May 1, 2006 Pasternak et al.	Vaccines: Market on the Rebound The vaccine business was safely inoculated against higher profits. But innovative therapies and looser government controls may spark an outbreak. Are pharmaceuticals ready for this opportunity?
The Motley Fool December 18, 2007 Brian Lawler	Cervarix Won't Save Glaxo Yet The FDA has another delay for this HPV vaccine. The agency has completed its review, but still has questions.
The Motley Fool December 30, 2008 Brian Orelli	A Shot in the Arm for Novartis' Pipeline The company picks up the rights to a vaccine that fights a virus.
The Motley Fool January 28, 2010 Brian Orelli	Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds.
The Motley Fool June 26, 2008 Brian Orelli	The FDA's Latest Victim Merck fails to get its Gardasil vaccine approved to treat older women.
The Motley Fool September 24, 2009 Brian Orelli	Drugmakers' HIV Treatments Live On Companies that make HIV drugs could lose billions of dollars in revenue if an effective vaccine is developed. All drug-company investors need to keep an eye on up-and-coming drugs from competitors that could take market share.
The Motley Fool October 15, 2009 Brian Orelli	An Ode to Wyeth Pfizer weds Wyeth today and the WYE ticker will be gone forever.
Pharmaceutical Executive August 1, 2011 Jill Wechsler	The Supremes Shape Pharma A number of important decisions from the Supreme Court will affect drug marketing, research, and regulation
The Motley Fool January 31, 2007 Brian Gorman	Merck's Special Interest Merck is likely to succeed in getting states to mandate HPV vaccination. Still, investors shouldn't necessarily bet everything on Gardasil.
The Motley Fool May 10, 2011 Brian Orelli	Pfizer's Multibillion-Dollar Blockbuster Set to Grow Pfizer will make money off old people, too.
Pharmaceutical Executive February 1, 2007 Beth Herskovits	Brand of the Year A first annual Brand of the Year honor goes to Gardasil, Merck's breakthrough vaccine for human papillomavirus.
The Motley Fool October 26, 2011 Chris Baines	Why Getting A Flu Shot Is Critical Vaccines save the lives of millions. By getting a flu shot, you're also aiding future vaccine research conducted by major pharmaceutical companies.
The Motley Fool November 6, 2007 Brian Orelli	Getting Vaccinated Alongside Mom Merck presents data supporting use of its HPV vaccine in older women. The drugmaker may have a tough marketing job ahead of it.
BusinessWeek August 27, 2009 Arlene Weintraub	Is Merck Overselling a Cancer Vaccine? Fresh controversies are heating up over the marketing of products to prevent cervical cancer.
Pharmaceutical Executive July 3, 2007 Jill Wechsler	Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries.
Pharmaceutical Executive July 10, 2014 Fitzpatrick & Mohan	Vaccines: Fire in the Cold Chain It's only recently that vaccine producers experienced the commercial returns commensurate with vaccines: long record of positive public health performance.